Brooke Swearingen, MD; Beverly M.K. Biller, MD; Fred G. Barker, MD; Laurence Katznelson, MD; Steven Grinspoon, MD; Anne Klibanski, MD; Nicholas T. Zervas, MD
Untreated Cushing disease historically has a high mortality rate, but the long-term survival of patients with Cushing disease after transsphenoidal surgery has not been reported.
To determine long-term mortality rate in patients who are treated for Cushing disease with current management techniques.
Retrospective case series.
Tertiary care center.
161 patients (32 men and 129 women; mean age, 38 years) who were treated for Cushing disease between 1978 and 1996.
Transsphenoidal adenomectomy and as-needed adjunctive therapy.
Record review with follow-up interview.
The cure rate for patients with microadenomas who had no previous therapy was 90% (123 of 137). No perioperative deaths occurred (0 of 193 procedures [95% CI, 0.0% to 1.9%]). Follow-up data (mean, 8.7 years) were obtained for 99% of patients (159 of 161). Six patients died. The 5- and 10-year survival rates were 99% (CI, 97% to 100%) and 93% (CI, 88% to 99%), respectively. Survival was similar to that seen in an age- and sex-matched sample that was based on U.S. population data (standardized mortality ratio, 0.98 [CI, 0.44 to 2.2]; P > 0.2).
Survival of patients treated for Cushing disease with current management techniques between 1978 and 1996 was better than the poor survival historically associated with this disorder.
Learn more about subscription options.
Register Now for a free account.
Swearingen B, Biller BM, Barker FG, Katznelson L, Grinspoon S, Klibanski A, et al. Long-Term Mortality after Transsphenoidal Surgery for Cushing Disease. Ann Intern Med. 1999;130:821-824. doi: 10.7326/0003-4819-130-10-199905180-00015
Download citation file:
Published: Ann Intern Med. 1999;130(10):821-824.
Adrenal Disorders, Endocrine and Metabolism.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only